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ABSTRACT
Helminth infections are widespread in the poultry industry. There is evidence of extra-label use of
some drugs, such as ivermectin (IVM), in broiler poultry. Pharmacokinetic and residual studies of
IVM in poultry, however, are rather scarce. Our aim was to determine time restrictions for broiler
chickens fed with balanced feed mixed with IVM for 21 days, and thus achieve acceptable
residual levels for consumption as established by the European Union. Sixty 1-day-old chicks
were fed with food supplemented with IVM at 5 mg kg–1 feed for 21 days. Groups of six treated
animals were sacrificed at 0, 1, 2, 4, 8, 10, 15, 20 and 28 days after treatment. Liver, skin/fat, kidney
and muscle samples were obtained. IVM were determined by liquid chromatography with
fluorescence detection after automatic solid-phase extraction with SPE C18 cartridges. The highest
concentrations were measured in the liver, which is logical given that IVM is a drug that under-
goes extensive hepatic metabolism. The optimal withdrawal time for edible tissues of these
animals to stay within the permitted residual levels were: 12 days for liver, 8 days for skin/fat,
0 days for muscle and 10 days for kidney.
ARTICLE HISTORY
Received 8 September 2016






Domestic birds are frequently affected by internal
parasites (Capillaria spp., Ascardia spp., Heterakis
gallinarum, Syngamus trachea) and external parasites
(Dermanyssus gallinae, scabies mites –
Cnemidocoptes mutans, fleas – Ceratophyllus galli-
nae, and some ticks – Argas persicus) (Sharma
et al. 1990; Bennett & Cheng 2012). Another ecto-
parasite of great economic impact on the poultry
farm is the beetle poultry litter, Alphitobius diaper-
inus, with a significant negative impact on perfor-
mance and production of birds. Ascaridia galli is an
important nematode parasite of poultry; heavy infec-
tion causes death of the chickens, whereas moderate
to low infection interferes with growth and produc-
tivity (Sharma et al. 1990). The control of this nema-
tode infection using anthelmintics through
medicated feed or water has reduced losses in the
poultry industry. Currently, formulations based on
ivermectin (IVM) for the treatment of parasitic
infections of birds are available on the market, but
they have not yet been approved for use in avian
species and, therefore, there are still no studies on
the profile of tissue depletion of these molecules in
chickens destined for human consumption.
It is well established that the efficacy of any anthel-
mintic drug depends not only on its affinity for specific
parasite target sites but also on its ability to reach high
and sustained drug concentrations where the parasites
are located. IVM is one of themost useful anti-parasitic
agents (Mestorino et al. 2003). It is a member of the
macrocyclic lactone family known as avermectins
(AVM) derived from Streptomyces avermitilis
(Echeverría et al. 2002), endectocides of wide spectrum
of activity at low doses rates with high potency and low
mammalian toxicity (Galarini et al. 2013) widely used
for treatment and prevention of internal and external
parasites in food-producing animals (Mestorino et al.
2003). IVM is effective when administered orally, par-
enterally or topically, and absorption is rapid by any of
these routes (Echeverría et al. 2002). This compound –
when administered in water – was effective in remov-
ing Ascaris galli, Heterakis gallinarum and Capillaria
spp. in poultry (Schepkins et al. 1985; Sharma et al.
1990; Todisco et al. 2008; Khayatnouri et al. 2011). It is
a very lipophilic molecule, so residues remain for long
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periods in the treated animal tissues, especially those
with a high fat content (Baynes et al. 2000). Until
recently, there were some oral formulations to control
internal and external parasites in game birds and fight-
ing cocks in some countries, but most are no longer
available on the market. In addition, no IVM formula-
tions for avian production were available. However,
extra-label use of this drug has been reported
(Bennett & Cheng 2012).
Residue studies are of fundamental importance in
public health. Consumer safety is based on a series of
measures includingMRLs and ADIs as the most impor-
tant. MRLs have been established by Commission reg-
ulations 37/2010, 418/2014 and 1390/2014 (EU 2010,
2014a, 2014b) for some AVMs in specific animal tissues
(bovine, ovine, caprine, equine, fish), but there are no
established MRLs for edible tissues of chicken. The
European Union set the MRLs for IVM in edible tissues
of food-producing mammals as follows: 100 ng g–1 in
liver and fat, and 30 ng g–1 in kidney and muscle.
Extrapolation of MRLs to the relevant minor species
has been considered.
The aim of this study was to determine restriction
periods for broiler chickens fed with a balanced feed
mixed with premix containing IVM for 21 days in
order to establish acceptable residual levels for human
consumption according to EuropeanUnion regulations.
Materials and methods
Reagents and chemicals
Ivermectin (IVM) pure reference standard (97%
purity) was obtained from Sigma Chemical Co. (St.
Louis, MO, USA). Acetonitrile and methanol solvent
used during the extraction and drug assay were of
HPLC grade and purchased from J. T. Baker
(Phillipsburg, NJ, USA). The N-methylimidazole
and trifluoroacetic anhydride used for the derivatisa-
tion reaction were from Sigma-Aldrich Chemical
Co. (Milwaukee, WI, USA). Solid-phase extraction
(SPE) columns (Strata, C18, 100 mg, 1 ml) and ana-
lytical column (Kinetex C18) were obtained from
Phenomenex (Torrance, CA, USA).
Study design treatment and administration
It is a common practice in the poultry industry to
dose chickens by adding IVM to the feed or in the
water system. Sixty-one-day-old BB chicks were fed
with a pre-start and initiator feed supplemented with
IVM at 5 mg kg–1 for 21 days. This means that if in
21 days a chicken consumes 1 kg of feed during the
same time it also consumes 5 mg of IVM (238 µg
day–1). We were not able to measure feeding rates in
this study. However, according to Cobb-Vantress
(2010), chicks of 1, 7, 14 and 21 days old eat
approximately 13, 28, 68 and 111 g day–1.
Assuming this intake, chicks in this study would
have approximately consumed 65, 140, 340 and
555 µg of IVM, respectively. Considering the chicks’
body weight: 185 g (1–7 days), 465 g (7–14 days) and
943 g (14–21 days), the estimate daily IVM dosage
was between 757 and 588 µg kg–1.
The chickens treated with IVM were euthanised
by cervical dislocation after desensitisation by pas-
sage of an electric current through the head in
groups of six animals at 0, 1, 2, 4, 8, 10, 15, 20 and
28 days post-treatment. The last time corresponds to
the sacrifice for commercials purposes. Six chickens
used as control (free of IVM) were euthanised before
the experiment. Immediately after slaughter, liver,
skin/fat, muscle and kidney samples were collected.
Each sample was properly conditioned, placed in
plastic bags, heat sealed, labelled and stored at –20°
C until assay.
The protocol followed the Guide for the Care and
Use of Agricultural Animals in Agricultural
Research and Teaching (Federation of Animal
Science Societies – FASS) and was approved by the
Experimental Ethics Committee of the Faculty of
Veterinary Science, UNLP, Argentina.
Ivermectin analysis
All tissue samples were analysed by HPLC with
automated SPE and fluorescence detection following
an adapted version of the methodology previously
described (Echeverría et al. 2002; Mestorino et al.
2003). Tissue samples (muscle, liver, kidney and skin
plus fat) were thinly sliced and 2 g were homoge-
nised in 1 ml of acetonitrile (Ultra Turrax T25 basic,
IKA, Works Inc., Lincoln, NE, USA). The homo-
genate was mixed for 20 min, sonicated for 10 min
(ultrasound bath) and centrifuged at 2000g for
10 min at 4°C. The clear supernatant was transferred
to a new tube and the extraction procedure was
repeated once. The total supernatant obtained was
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placed on the appropriate rack of Aspec XL auto-
matic SPE apparatus (Gilson, Villiers-le-Bel, France).
Automatic sample preparation was performed using
SPE C18 cartridges (Strata C18, 100 mg, 1 ml,
Phenomenex), which were conditioned with 2 ml
of methanol, and followed by 2 ml of water HPLC
quality. All samples were applied to cartridges,
washed with 1 ml of water followed by 1 ml of
methanol/water (1:3, v/v), dried with air for 2 min
and finally eluted with 3 ml of methanol of HPLC
grade. The eluted volume was evaporated at 60°C to
dryness in a vacuum concentrator (AVC 2-25CD
Christ, Osterode, Germany). A fluorescent derivative
was obtained by dissolving the dry residue in 100 µl
of a mixture of N-methylimidazole solution in acet-
onitrile (1:1, v/v). To initiate the derivatisation,
150 µl of a solution of trifluoroacetic anhydride in
acetonitrile (1:2, v/v) were added. After completion
of the reaction (< 30 s) and mixing, the solution was
transferred to autosampler polypropylene vials and
an aliquot of 100 µl was injected into the chromato-
graphic system. HPLC analyses were carried out
within 4 h to avoid the degradation of the fluores-
cent derivatives.
Standard curve
Standards were prepared by adding 0.5, 1, 2.5, 5, 10,
20 and 30 ng of IVM to test tubes, evaporating to
dryness at 60ºC, and dissolving and derivatising as
described above. Linear regression analysis using a
least-square fit was performed.
Chromatographic conditions
The chromatographic system consisted of an iso-
cratic pump (Gilson Inc. 307), an automatic injector
(Gilson Inc. 234), a FluoroMonitor IM III Detector
(Sp Thermo Separation products) set at an excitation
wavelength of 365 nm and an emission wavelength
of 475 nm, and Eppendorf CH-30 Column Heater
(set at a 30ºC). The system is controlled through the
Unipoint® Gilson system. An C18 column (Kinetex,
2.6 µm, 4.6 mm × 100 mm; Phenomenex) and was
eluted with a mixture of acetic acid 2% in water–
methanol–acetonitrile (4:32:64) at a flow rate of
1.5 ml min–1 at 30°C. Identification of IVM in bird
tissues was accomplished by comparison with the
retention times of the reference standards.
The precision of the extraction procedure and
chromatography technique were evaluated by pro-
cessing as replicates in six different occasions ali-
quots of pooled different tissue samples containing
known amounts of IVM.
Method validation
The method for the identification of IVM in tissue
broilers was validated in terms of the analytical para-
meters of linearity, precision, accuracy, LOQ and
LOD, and selectivity following the guideline for the
validation of analytical methods used in residue-
depletion studies from the International
Cooperation on Harmonization of Technical
Requirements for the Registration of Veterinary
Medicinal Products (VICH 2015).
Linearity was determinate using seven concentra-
tions of IVM standard (0.5, 1, 2.5, 5, 10, 20 and 30
ng ml–1) injected three times into the chromatogra-
phy system.
Blank tissue samples were fortified with IVM
ranging between 0.5 and 30 ng g–1. IVM concentra-
tions were determined from peak areas and the use
of calibration curves obtained by running tissue
samples from chickens not treated with IVM (i.e.,
chicken control) that were spiked with known con-
centrations of IVM. For tissue specimens as deter-
mined using the linear least squares regression
procedure, a linear relationship existed in the cali-
bration curve of IVM over the range of 0.5–30 µg g–1
for muscle, liver, kidney and skin plus fat.
Precision and accuracy of the method were deter-
mined by the evaluation of replicates of IVM-free
samples (n = 6) fortified with IVM at different con-
centrations (0.5, 5, 20, 30 ng g–1). Precision was
expressed as coefficient of variation (% CV).
Accuracy, defined as the closeness between the
experimentally measured and the true value, was
determined by the differences between observed
and calculated concentration results, and expressed
as the relative error (% RE) (Chandran & Singh
2007).
The LOQ was calculated as the lowest IVM con-
centration (n = 6) on the standard curve that could
be quantitated with precision not exceeding 20% and
accuracy within 20% of nominal. The LOD was
estimated by the analysis of 10 aliquots of control
tissue (free of IVM). The noise of the baseline was
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measured; the average and standard deviation were
calculated; the LOD corresponded to three times the
SD (sign/noise ≥ 3/1).
Selectivity is the ability of the method to distin-
guish between the analyte being measured and other
different substances that might be present in the
sample being analysed. The selectivity of the method
was determined by comparing the chromatograms of
IVM-free tissue samples with those of each tissue
fortified with IVM. The lack of interferences in the
separation suggests a high specificity of the chroma-
tographic method and good selectivity of the extrac-
tion procedure. Tissue concentrations were
expressed as ng g–1.
Withdrawal time
The withdrawal periods for edible tissues of chickens
(muscle, liver, kidney and skin plus fat) were esti-
mated by linear regression analysis of the log-trans-
formed tissue concentrations and determined at the
time when the upper one-sided 95% tolerance limit
for the residue was below the MRL, with a confi-
dence of 95% (EMEA 2002). IVM concentrations as
a function of time found in muscle, kidney, liver and
skin/fat were plotted and analysed with the program
WT version 1.4 in order to recommend a period of
withdrawal time for this experimental formulation.
Results
No adverse response was observed after feeding with
feed supplemented with IVM at 5 mg kg–1 during
21 days. This method performed accurately and
reproducibly over a range of 0.5–30 ng g–1 for
IVM. The linear regression equation obtained for
the proposed HPLC method as calibration curve
was y = (1.6884E–5 ± 0.0695)x + (0.2962 ± 0.0867)
(r = 0.9969 ± 0.00076), where y is the area ratio; and
x is the analyte concentration (ng ml–1). The chro-
matographic analysis time was short and IVM was
presented in 2.04 ± 0.4 min, and no peaks were
observed in the vicinity of IVM retention time,
attesting the method’s selectivity (Figure 1).
Precision and accuracy of the method were deter-
mined by evaluation of replicates of drug-free sam-
ples (n = 6) fortified with IVM at different
concentrations (0.5, 5, 20, 30 ng g–1). Table 1
shows the validation parameters (R2, percentage
recovery, precision (% CV), accuracy (% RE) and
LOD) for different tissues spiked with 0.5, 5, 20 and
30 ng g–1 of IVM. The mean global percentage of
recoveries were 91.8%, 92.6%, 93.9% and 91.6% in
liver, kidney, muscle and fat respectively, with CVs
of 4.0%, 1.5%, 2.8% and 2.9% respectively. For indi-
vidual levels and the overall evaluation of the work-
ing range, satisfactory results in the region of
70–120% were obtained. Within-laboratory preci-
sions were ≤ 20% for the working range. The LOQ
for each tissue assayed was 0.5 ng g–1, the lowest
concentration of IVM residues evaluated with accep-
table accuracy and precision, applying the complete
analytical method here presented. The calculated
LODs are presented in Table 1.
The validation method used here indicated that
the analytical method used to extract, derivatise and
quantify IVM in chicken tissues by chromatographic
analysis using a fluorescence detector was
appropriate.
IVM tissue concentrations
Table 2 shows the mean ± SD tissue concentrations
of IVM in muscle, kidney, liver and skin plus fat on
different days after the end of treatment. The residue
levels were low, with the highest concentration mea-
sured between the first and second days post-treat-
ment in all tissues. The tissue with the highest
concentration was liver, followed by skin/fat, kidney,
and muscle. The higher concentrations were found
in liver tissue, which is logical since IVM is a mole-
cule that undergoes extensive hepatic metabolism,
mainly by hydroxylation processes.
Considering that IVM was administered with
food, concentrations found in different tested tissues
were highly variable.
Linear regression analysis of the logarithmic trans-
formed data can be considered for the calculation of
the withdrawal periods. Using this approach, the with-
drawal time is determined as the time when the one-
sided 95% upper tolerance limit of the regression line
with a 95% confidence level is below the MRL.
According to the residual concentrations found, opti-
mal withdrawal times for edible tissues were 12 days
for liver, 8 days for skin/fat and 10 days for kidney
(Figure 2). In muscle tissue the concentrations found
were always below the MRL established (30 ng g–1),
that way the assay did not give any withdrawal time.
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Figure 1. (colour online) Chromatograms of 5 ng ml–1 IVM standard (A), liver sample obtained at 0 day post-treatment to animal 5
(B), liver tissue fortified with 5 ng g–1 of IVM (C) and liver control (blank).
Table 1. Validation parameters for the determination of ivermectin residues in chicken tissues.
Parameter
Chicken tissue
Liver Kidney Muscle Skin/fat
R2 0.9969 0.9985 0.9957 0.9970
0.5 ng g–1 (n = 6)
Recovery (%) ± SD 95.6 ± 5.1 98.6 ± 0.2 101.1 ± 3.0 96.2 ± 2.2
Precision (% CV) 5.3 0.2 3.0 2.6
Accuracy (% RE) ± SD –4.4 ± 5.1 –1.4 ± 0.2 1.1 ± 3.0 –3.8 ± 2.2
5.0 ng g–1 (n = 6)
Recovery (%) ± SD 88.5 ± 2.7 92.4 ± 3.1 89.9 ± 5.4 94.3 ± 3.6
Precision (% CV) 3.0 3.4 6.0 3.9
Accuracy (% RE) ± SD –11.5 ± 2.7 –7.6 ± 3.1 –10.0 ± 5.4 –5.7 ± 3.6
20 ng g–1 (n = 6)
Recovery (%) ± SD 87.5 ± 2.6 81.3 ± 1.5 85.2 ± 0.6 83.7 ± 1.9
Precision (% CV) 3.0 1.87 0.6 2.3
Accuracy (% RE) ± SD –12.6 ± 2.6 –18.7 ± 1.5 –14.9 ± 0.6 –16.3 ± 1.9
30 ng g–1 (n = 6)
Recovery (%) ± SD 95.5 ± 4.6 98.1 ± 0.7 99.5 ± 1.4 93.4 ± 2.9
Precision (% CV) 4.8 0.7 1.4 3.1
Accuracy (% RE) ± SD –4.5 ± 4.6 –1.9 ± 0.7 –0.5 ± 1.4 –6.6 ± 2.9
Overall evaluation over the working range
Recovery (%) ± SD (n = 24) 91.8 ± 4.4 92.6 ± 8.1 93.9 ± 7.6 91.6 ± 5.6
Precision (% CV) 4.0 1.5 2.8 2.9
Accuracy (% RE) ± SD –7.0 ± 3.3 –5.1 ± 4.0 –2.6 ± 5.0 –5.0 ± 1.4
LOD (ng g–1) 0.11 0.07 0.05 0.09
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Discussion and conclusions
Regarding the analytical methodology, for the
working range evaluated, recovery and precision
are according to the performance criteria for con-
sidering a quantitative method suitable for the
determination of veterinary drug residues in foods
when the concentration is between 1 and 100 µg g–
1 (FAO & OMS 2009).
IVM is used in different animals (cattle, sheep, goats,
pigs, horses) at dose rates of 100–500 µg kg–1 by sub-
cutaneous, topical or oral routes, as a single-dose treat-
ment only. Furthermore, it has also been studied in other
animal species such as wild ruminants (reindeer, deer,
camels and American bison) for which IVM extra-label
use has been reported (Gonzalez-Canga et al. 2012;
Moreno et al. 2015).
In poultry, anti-parasitic compounds are used
extensively for disease prevention and treatment.
Sharma et al. (1990) evaluated the IVM efficacy
against Ascaridia galli infection in chickens at a
dose of 300 µg kg–1 subcutaneously, finding an effi-
cacy between 90% and 95% against immature and
adult worms. Moreover, they found that the treated
birds also had a better growth rate than the
untreated control chickens.
In addition to controlling parasites effectively,
some authors found an immunostimulatory effect
Table 2. Mean ± SD of ivermectin (ng g–1) concentrations measured in the depletion study in
chickens after oral administration of IVM during 21 days with the food.
Days post-
treatment Kidney ± SD Liver ± SD Skin/fat ± SD Muscle ± SD
0 9.57 ± 3.58 38.32 ± 13.33 7.91 ± 3.73 8.63 ± 3.18
1 18.92 ± 5.88 73.54 ± 36.40 5.86 ± 3.12 4.49 ± 2.52
2 6.55 ± 2.93 124.10 ± 65.54 49.41 ± 29.72 2.55 ± 2.68
4 5.89 ± 3.79 3.76 ± 3.03 14.06 ± 11.76 2.94 ± 2.61
8 2.28 ± 1.87 52.88 ± 26.11 32.37 ± 15.01 2.29 ± 0.47
10 7.38 ± 3.67 18.19 ± 13.95 26.71 ± 10.17 1.53 ± 1.09
15 7.14 ± 3.86 1.12 ± 0.19 3.11 ± 1.88 1.21 ± 0.34
21 7.06 ± 2.62 3.81 ± 2.65 2.19 ± 1.38 0.93 ± 0.34
28 4.70 ± 1.90 1.07 ± 0.05 2.01 ± 1.05 0.88 ± 0.30
Figure 2. Withdrawal times of IVM calculated by linear regression analysis for kidney (a), liver (b), skin/fat (c) and muscle (d)
(logarithmic transformed data).
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in broilers at a high-rate dose of IVM (5 mg kg–1)
(López-Olvera et al. 2006; Omer et al. 2012). Omer
et al. (2012) treated 20-day-old chickens with IVM at
dosage rates of 0.15, 0.3, 1, 3 and 5 mg kg–1 body
weight. In another study carried out by Khayatnouri
et al. (2011), the effect of IVM pour-on administra-
tion against Heterakis gallinarum infestation was
evaluated at a dose of 500 µg kg–1. They obtained a
reduction in egg count exceeding 98%, concluding
that IVM can be used in antiparasitic programmes in
poultry.
However, the available information reporting tis-
sue residue profiles after IVM treatment is scarce in
poultry compared with other species (Goetting et al.
2011; Moreno et al. 2015). Edible tissues containing
veterinary drug residues can pose risks to human
health, including direct toxic effects, allergic reac-
tions and increased parasites resistance (Ōmura &
Crump 2014).
Macrolide endectocides, such as IVM, are lipo-
philic compounds, so high concentrations will be
found in edible tissues, particularly in those with a
high fat content, where they can persist for pro-
longed periods (Canga et al. 2009). IVM is not
highly metabolised and excretion is primarily via
the faeces (Canga et al. 2009).
When IVM is administered to laying hens, resi-
dues are preferentially deposited in the egg yolk
(Keukens et al. 2000; Moreno et al. 2015) and can
be found in eggs laid for several days following
cessation of treatment. Moreno et al. (2015) treated
laying hens with IVM administered daily in water at
400 µg kg–1 dose for a 5-day period. They quantified
IVM residues for a longer time in skin/fat until
15 days post-treatment, in the case of muscle and
liver until 7 days after the end of treatment, and
IVM kidney residues were measured only 3 days
post-treatment. In contrast, Bennett and Cheng
(2012) treated adult pigeons brooding squab with
IVM in drinking water (3.3 µg ml–1) for 3 days and
found high IVM residue concentrations in both liver
(58.5 ng g–1) and breast muscle (43.1 ng g–1) at the
end of treatment. In the present study, we found
measurable concentrations below the MRL in all
tissues until 28 days post-treatment. These differ-
ences can be explained by the vehicle used to solu-
bilise the IVM. Moreno et al. (2015) and Bennett
and Cheng (2012) used drinking water and we used
initiator chickens’ feed. The main drinking water
medication disadvantages are related to the several
factors that influence individual animal water intake,
including biological (body weight, age), environmen-
tal (lighting period, environmental temperature) and
management factors (composition of the diet).
Our results do not match those of Miller (1990)
who administrated IVM to chickens with a diet of
2 µg g–1 of food for 5 weeks and found no residues
of IVM in their livers, so this author did not estab-
lish a withdrawal period. The study performed by
Miller was mainly about IVM efficacy against
Alphitobius diaperinus, not about tissue profile
depletion of IVM, where the experimental animals
were sacrificed at the end of the treatment (5 weeks),
therefore IVM residual levels in the liver were deter-
mined only at that sampling time.
In the European Union, MRLs of 100 (fat and liver)
and 30 ng g–1 (for kidney and muscle) are established
for IVM in all mammalian food-producing species.
Withdrawal periods of 35, 28 and 18 days are recom-
mended after IVM administration by the subcuta-
neous route in cattle, sheep and pigs, respectively. In
some Latin American countries there are some IVM
commercial formulations for use in the poultry indus-
try. They are usually administered in water or food for
2, 3, 5 or 21 days. Withdrawal times are recommended
in some of these formulations (2 or 7 days for meat
and 0 days for eggs). According to European Union
regulations, chickens fed for 21 days with this type of
supplement containing IVM (5 mg kg–1) would be
suitable for human consumption at 12 days post-treat-
ment, i.e., at 33 days of life in this case. Considering
that broiler chickens aged 45–54 days old are destined
for the market, it can be stated that with the dosage
scheme proposed in our study the chickens would be
suitable for human consumption. These results would
suggest that the IVM withdrawal period for growing
chickens could be shorter than that of mammals, but
pharmacokinetic studies need to be performed to test
this hypothesis.
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